Search Results - "Ottewell, L."

Co-proxamol: where have all the patients gone? by Ottewell, L., Walker, D. J.

Get full text

Systematic review of the impact of cannabinoids on neurobehavioural outcomes in preclinical models of traumatic and nontraumatic spinal cord injury by Bhatti, F., Mowforth, O., Butler, M., Bhatti, A., Adeeko, S., Akhbari, M., Dilworth, R., Grodzinski, B., Osunronbi, T., Ottewell, L., Teh, J. Quan, Robinson, S., Suresh, G., Waheed, U., Walker, B., Kuhn, I., Smith, L., Bartlett, R., Davies, B., Kotter, M.

Get full text

To Do No Good by Walker, D. J., Ottewell, L., Moots, R. J.

Get full text

Comment on: Micro magnetic resonance angiography of the finger in systemic sclerosis by McKay, N., Ottewell, L., Griffiths, B., Allen, J.

Get full text

The prevalence and significance of positive antinuclear antibodies in patients with fibromyalgia syndrome: 2-4 years' follow-up by Al-Allaf, A W, Ottewell, L, Pullar, T

“…The aim of this study was to ascertain whether fibromyalgia patients with positive ANA develop other features of connective tissue disease over 2-4 years'…”
Get full text

Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis by Warren, Richard B., Fu, Bo, Wilson, Anthony G., Fairburn, K., Hui, M., Coady, D., Morley, C., Bracewell, C., Armstrong, D., Hailwood, S., Kumar, N., O'Reilly, S. C., Ding, T., Badcock, L. J., Regan, M. R., Summers, G. D., Stevens, R., Kelly, C. A., Hamilton, J., Saravanan, V., Cope, A., Garrood, T., Das, D., Wakefield, R. J., Buch, M., Parker, B., Gaffney, K., Crook, P. R., Szebenyi, B., Gillott, T., McHale, J. F., Jones, A. C., Lanyon, P., Doherty, M., Abhishek, A., Das, L., Pattrick, M., Bowden, A. P., Speden, D. J., Ledingham, J. M., Cooper, A., Wong, E., Shaban, R., Woolf, A. D., Davis, M., Hutchinson, D., Kennedy, T. D., Bhalla, A., Dixon, W. G., Buckley, C. D., Carruthers, D. C., Grindulis, K. A., Raza, K., Till, S., Dunkley, L., Tattersall, R., Maxwell, J., Till, S., Kuet, K.-P., Plant, M. J., Clarke, F., Fordham, J. N., Pathare, S. K., Marguerie, C. P., Dunn, N., Clewes, A. R., Dawson, J. K., Klocke, R., John, H., Shand, L., Foster, H., Griffiths, B., Walker, D. J., Lorenzi, A., Friswell, M., Dunne, C. A., Mukherjee, S., Mulherin, D., Chalam, S. V., Price, T., McKenna, F., Allen, M., Chaudhuri, K., Dubey, S., Price‐Forbes, A., Samanta, A., Sheldon, P., Kinder, A., Neame, R., Bukhari, M., Hider, S., Hassell, A., Kamath, S., Packham, J., Dutta, S., Price, S., Quinn, D., Brown, A., Saleem, B., Foo, B.

“…Objective To investigate whether antidrug antibodies and/or drug non‐trough levels predict the long‐term treatment response in a large cohort of patients with…”
Get full text

Socioeconomic deprivation is associated with reduced response and lower treatment persistence with TNF inhibitors in rheumatoid arthritis by Zhao, Sizheng Steven, Rogers, Kira, Kearsley-Fleet, Lianne, Watson, Kath, Bosworth, Ailsa, Galloway, James, Verstappen, Suzanne, Plant, Darren, Barton, Anne, Hyrich, Kimme L, Humphreys, Jenny H

“…To investigate the association between socioeconomic deprivation and outcomes following TNF inhibitor (TNFi) treatment. Individuals commencing their first TNFi…”
Get full text

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis by Hum, Ryan M, Ho, Pauline, Nair, Nisha, Jani, Meghna, Morgan, Ann W, Isaacs, John D, Wilson, Anthony G, Hyrich, Kimme L, Plant, Darren, Barton, Anne

“…Abstract Objectives Interventions aimed at increasing TNF-α inhibitor serum drug levels (SDLs) may improve treatment response; however, previous studies…”
Get full text

Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis by Curry, Philippa D K, Hum, Ryan M, Morris, Andrew P, Jani, Meghna, Chinoy, Hector, Barton, Anne, Bluett, James

“…Up to 40% of psoriatic arthritis (PsA) patients experience first-line Tumour Necrosis Factor inhibitors (TNF-i) failure. Lower serum drug levels (SDL) have…”
Get full text

The influence of deprivation in the outcomes of psoriatic arthritis within the UK-utilizing Outcomes of Treatment in Psoriatic Arthritis Study Syndicate (OUTPASS) data by Lyon, Max, Zhao, Sizheng Steven, Jani, Meghna, Chinoy, Hector, Barton, Anne, Bluett, James

Get full text

Psoriatic arthritis: the role of self-reported non-adherence, non-trough drug levels, immunogenicity and conventional synthetic DMARD co-therapy in adalimumab and etanercept response by Curry, Philippa D K, Morris, Andrew P, Jani, Meghna, Chinoy, Hector, Barton, Anne, Bluett, James

“…Abstract Objective The aim of this study was to assess the relationship between self-reported non-adherence, non-trough drug levels, immunogenicity and…”
Get full text

Comment on: Micro magnetic resonance angiography of the finger in systemic sclerosis: reply by Wang, J., Yarnykh, V. L., Molitor, J. A., Nash, R. A., Chu, B., Wilson, G. J., Fleming, J., Schwartz, S. M., Yuan, C.

Get full text

Scleroderma and Related Disorders [202-212]: 202. Multi-Centre Audit of Treatment of Interstitial Lung Disease in Systemic Sclerosis with IV Cyclophosphamide by Yazdani, R., Abhishek, A., Fiona, P., Lim, K., Regan, M., Lanyon, P., Khan, K., Hoyles, R. K., Shiwen, X., Derrett-Smith, E., Abraham, D., Denton, C. P., Ottewell, L., Walker, K., Griffiths, B., Ali Nazarinia, M., Abbasi, N., Karimi, A., Amiri, A., Derrett-Smith, E. C., Baliga, R., Dooley, A., Shi-Wen, X., Stretton, K., Shukla, S., Hall, F., Nandagudi, A., Kingsley, G., Scott, D., Stratton, R., Leask, A., Guillevin, L., Krieg, T., Schwierin, B., Rosenberg, D., Silkey, M., Matucci-Cerinic, M., Jones, H., Bou-Gharios, G., So, P., Renzoni, E., Denton, C., Wells, A.

Get full text